No abstract

No abstract

This Phase III, randomized, double-blind, placebo-controlled, parallel-group, prospective study based on VAS evaluations clearly showed that orally taken nalfurafine hydrochloride effectively reduced itches that were otherwise refractory to currently available treatments in maintenance haemodialysis patients, with few significant ADRs. This novel drug was officially approved for clinical use in January 2009 by the Ministry of Health, Labour and Welfare of Japan.

Herein we demonstrate the extra-low-temperature oxygen storage capacity (OSC) of cerium oxide nanocrystals with cubic (100) facets. A considerable OSC occurs at 150 °C without active species loading. This temperature is 250 °C lower than that of irregularly shaped cerium oxide. This result indicates that cubic (100) facets of cerium oxide have the characteristics to be a superior low-temperature catalyst.

The synthesis, characterization, and reversible guest-exchange chemistry of a new porous magnetic material that orders ferrimagnetically at 60.5 K are described. The material, Co(5)(OH)(8)(chdc).4H(2)O (chdc = trans-1,4-cyclohexanedicarboxylate), contains tetrahedral-octahedral-tetrahedral Co(II)-hydroxide layers of composition Co((oct))(3)Co((tet))(2)(OH)(8) that are linked together by bis(unidentate) chdc pillars. Noncoordinated water molecules occupy 1-D channels situated between the chdc pillars. The material remains monocrystalline during dehydration from Co(5)(OH)(8)(chdc).4H(2)O (CDCC.4H(2)O) to Co(5)(OH)(8)(chdc) (CDCC) via an intermediate Co(5)(OH)(8)(chdc).2H(2)O (CDCC.2H(2)O) upon heating or evacuation. In-situ single crystal and powder X-ray diffraction analyses indicate that the interlayer spacing decreases in two steps, each corresponding to the loss of two water molecules per formula unit as determined by thermogravimetry. The single crystal structure of the fully dehydrated material, CDCC, has no void volume due to a tilting of the pillars and 9% decrease of the interlayer spacing with water removal. Exposure of CDCC to air causes rapid rehydration of this material to CDCC.4H(2)O, as determined by single crystal X-ray diffraction, powder X-ray diffraction, thermogravimetry, and vibrational spectroscopy. Both the hydrated and dehydrated forms order magnetically below 60.5 K. The susceptibility data are consistent with ferrimagnetic behavior, and the value of the saturation magnetization at 2 K (ca. 2 micro(B)) is explained by a model of two sublattices, one comprising three octahedral cobalt atoms and another comprising two tetrahedral cobalt atoms. There is an enhanced 2-D correlation within the layer at temperatures just above the Curie temperature, as seen by nonlinearity in the ac susceptibility data and remanence in the isothermal magnetization. The crossover from 2-D to 3-D ordering occurs at T(C). The large anisotropy in the magnetization data on a single crystal suggests either a 2-D Ising or an XY magnet while the critical exponent of 0.25 is in favor of the latter. Both magnetization data in a small field in the ac and dc mode and isothermal magnetization data provide evidence of a further change in behavior at 23 K, which may originate from a reorientation of the moments within the layer. Variation of the pillar and of the guest-exchange chemistry, including the exchange of magnetic guests such as O(2), offers the possibility of tailoring the magnetic properties of this material.

Background: Our previous placebo-controlled, prospective, double-blind study demonstrated that a new opioid ĸ-receptor agonist, nalfurafine hydrochloride, effectively reduced treatment-resistant pruritus in 337 hemodialysis patients. Thus, we designed this study to evaluate prospectively the efficacy, safety, addiction liability, and pharmacokinetics of nalfurafine given orally for 1 year. Methods: This open-label study examined the effects and adverse drug reactions (ADRs) of 52-week oral administration of nalfurafine hydrochloride (5 µg/day) in 211 hemodialysis patients with a treatment-resistant itch. Results: Of 211 patients, 145 completed the study as scheduled. The mean pruritus value assessed by the visual analogue scale was 75.2 mm during the pre-observation period, which decreased significantly to 50.9 and 30.9 mm in week 2 and 52, respectively, indicating a long-lasting efficacy. ADRs occurred in 103 patients (48.8%). Frequent ADRs were insomnia (sleep disturbance, 19.4%), constipation (7.1%) and increased blood prolactin (3.3%), similar to previous reports. Regarding addiction liability, it appeared unlikely that nalfurafine hydrochloride was abused. After the start of treatment, plasma drug levels reached a steady state in week 2 with no apparent tendency of systemic accumulation. Conclusions: Nalfurafine hydrochloride, orally administered at 5 µg/day for 52 weeks to hemodialysis patients, produced a long-term suppression of pruritus without significant safety problems.

Reversible crystal-to-crystal transformation accompanied by change from ferromagnetic to antiferromagnetic ground states at 8 K upon dehydration-rehydration of the nanoporous coordination framework [CoII3(OH)2(C4O4)2].3H2O.

No abstract